E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with first relapse or progression of aggressive Non-Hodgkin’s Lymphoma who are not eligible neither for autologous nor allogeneic stem cell transplantation |
|
E.1.1.1 | Medical condition in easily understood language |
Patients with first relapse or progression of aggressive Non-Hodgkin’s Lymphoma who are not eligible neither for autologous nor allogeneic stem cell transplantation |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Blood and lymphatic diseases [C15] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 22.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10029547 |
E.1.2 | Term | Non-Hodgkin's lymphoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Improvement of 1-yr PFS by nivolumab plus (R)-GemOx followed by nivolumab consolidation instead of (R)-GemOx alone in patients with progressed or relapsed aggressive NHLs not eligible neither for autologous nor allogeneic stem cell transplantation |
|
E.2.2 | Secondary objectives of the trial |
- To determine whether survival can be increased by adding nivolumab to standard (R)-GemOx. - To determine whether outcome can be improved by adding nivolumab to standard (R)-GemOx. - To determine toxicity and protocol adherence of standard (R)-GemOx with or without nivolumab. - To evaluate quality of life of patients with relapsed or refractory aggressive Non-Hodgkin’s Lymphoma treated with (R)-GemOx with or without Nivolumab. - To analyze outcome according to biological parameters.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Age: all patient >65 years of age or > 18 years if not eligible for neither autologous nor allogeneic stem cell transplantation 2. Ineligibility for neither autologous nor allogeneic stem cell transplantation as defined as: >65 years of age or older than 18 years if HCT-CI score > 2 (cf. Appendix 24.2) or patients who underwent prior autologous stem cell transplantation and are not eligible for allogeneic stem cell transplantation 3. Risk group: All risk groups (IPI 0 to 5) 4. Histology: Diagnosis of aggressive Non-Hodgkin’s lymphoma, based on an excisional biopsy of a lymph node or on an appropriate sample of a lymph node or of an extranodal involvement at initial diagnosis or relapse or progression.The entities treated in the study will be based on the WHO 2017 classification62. B-NHL: Follicular lymphoma grade IIIb DLBCL, not otherwise specified (NOS) T-cell/histiocyte-rich large B-cell lymphoma primary cutaneous DLBCL, leg type EBV-positive DLBCL, NOS DLBCL associated with chronic inflammation primary mediastinal (thymic) large B-cell lymphoma intravascular large B-cell lymphoma ALK-positive large B-cell lymphoma plasmablastic lymphoma primary effusion lymphoma HHV8+ DLBCL, NOS high-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements high-grade B-cell lymphoma, NOS B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma T-NHL: Aggressive NK cell leukemia Enteropathy-associated T-cell lymphoma Hepatosplenic T-cell lymphoma Primary cutaneous gamma-delta T-cell lymphoma Peripheral T-cell lymphoma, NOS Angioimmunoblastic T-cell lymphoma Anaplastic large cell lymphoma, ALK-positive Anaplastic large cell lymphoma, ALK-negative Peripheral T-cell lymphoma with TFH phenotype Monomorphic epitheliotropic intestinal T-cell lymphoma Subcutaneous panniculitis-like T-cell lymphoma 5. Performance status: Performance status ECOG 0 – 2. Also patients with performance status 0 – 2 are eligible when assessed after prephase treatment. The performance status of each patient should be assessed before the initiation and after the end of prephase treatment which, as experience has shown, can result in its significant improvement. A definition of the performance status is provided in Appendix 24.3. 6. Previous therapy: Patients must have only one prior chemotherapy regimen including an anthracycline. The last cytotoxic drug must be given at least four weeks prior randomization. Rituximab must be part of the first-line regimen in case of B-cell lymphoma (except for primary CD20- negative lymphoma). Patients may have received prior radiation therapy as part of their first-line therapy. 7.Men who are sexually active with women of childbearing potential (WOCBP) must use any contraceptive method with a failure rate of less than 1% per year. Men who are sexually active with women of childbearing potential (WOCBP) must not father a child during and up to 6 months after GemOx and up to 12 months after Rituximab and/or Nivolumab. They are advised to do cryoconservation of sperm prior to treatment. Women who are not of childbearing potential ie, who are postmenopausal or surgically sterile as well as azoospermic men do not require contraception. A WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 62 must have a documented serum follicle stimulating hormone (FSH) level higher than 40 mIU/mL. 8. Written informed consent of the patient 9. Patient must be covered by social security system. |
|
E.4 | Principal exclusion criteria |
1. Already initiated lymphoma therapy after first relapse or progression (except for the prephase treatment, cf. 8.6.1). 2. Serious accompanying disorder or impaired organ function (except when due to lymphoma involvement), in particular: heart: angina pectoris CCS >2, cardiac failure e.g. NYHA >2 liver: total bilirubin >1.5 times the upper reference limit (except subjects with Gilbert Syndrome, who can have total bilirubin <51 μmol/l), aspartate transaminase (AST) or alanine transaminase (ALT) >3 x institutional upper reference limit kidney: creatinine clearance < 30 ml/min 3. WBC < 2.5 G/l, Neutrophils <2 G/l, Platelets <100G/l (does not apply if cytopenia is caused by lymphoma) 4. Prolongation of QTc interval > 450 ms, demonstrated in one electrocardiogram (done as triplicate). This does not apply for patients with a block of the right and/or left bundle branch. 5. Family history for Long QT-syndrome 6. Patients with an active, known or suspected autoimmune disease. Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger 7. There must also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration (except for treatment of lymphoma). 8. Chronic active hepatitis B or C as defined either HBs Ag positive or HBc Ac positive with detectable viral DNA or hepatitis C virus ribonucleic acid positive. 9. HIV-infection 10. Patients with a severe immunodeficiency 11. Previous therapy with Nivolumab, Gemcitabine or Oxaliplatin. 12. Patients with a “currently active” second malignancy other than non-melanoma skin cancer. Patients are not considered to have a “currently active” malignancy if they have completed therapy since 6 months and are considered by their physician to be less than 30% risk of relapse within one year. 13. CNS involvement of lymphoma (intracerebral, meningeal, intraspinal intradural) or primary CNS lymphoma 14. Persistent neuropathy grade >2 (NCI CTC-AE v4.03) (unless due to lymphoma involvement) 15. Pregnancy or breast-feeding women 16. Women of childbearing potential (WOCBP). A WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 62 must have a documented serum follicle stimulating hormone (FSH) level higher than 40 mIU/mL. 17. Active serious infections not controlled by oral and/or intravenous antibiotics or antifungal medication 18. Any medical condition which in the opinion of the investigator places the subject at an unacceptably high risk for toxicities 19. Lymphomas other than those listed in the inclusion criteria notably indolent lymphoma, Mantle cell lymphoma, Burkitt lymphoma, adult T-cell leukemia/lymphoma. 20. Persons not able to understand the impact, nature, risks and consequences of the trial (including language barrier) 21. Persons not agreeing to the transmission of their pseudonymous data 22. Persons depending on sponsor or investigator 23. Persons from highly protected groups 24. Allergies and Adverse Drug Reaction History to study drug components 25. Participation in another clinical trial with drug intervention within 4 weeks prior to start of the first cycle and during the study. However, participation in a clinical trial of firstline therapy of lymphoma is allowed. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Progression-free survival |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1 year (data collected during the restagings and the follow-up assessments as planned in the protocol (cf. chapter 8.9 in the protocol)) |
|
E.5.2 | Secondary end point(s) |
•complete response rate •partial response rate •overall response rate •duration of response •progression rate •rate of treatment-related deaths •relapse rate •Event-free survival •Overall survival •Toxicity •Protocol adherence •quality of life as assessed by the EQ-5D-5L. •outcome according to PD-L1 and PD-1 expression, cell of origin, 9p24.1 alterations
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
•complete response rate , partial response rate, overall response rate : (data collected during the restagings and the follow-up assessments as planned in the protocol (cf. chapter 8.9 in the protocol)) •duration of response : end of study •progression rate : end of study •rate of treatment-related deaths : end of study •relapse rate : end of study •Event-free survival : end of study •Overall survival : end of study •Toxicity : end of study •Protocol adherence : end of study •quality of life as assessed by the EQ-5D-5L : end of study •outcome according to PD-L1 and PD-1 expression, cell of origin, 9p24.1 alterations : end of study
(data collected during the restagings and the follow-up assessments as planned in the protocol (cf. chapter 8.9 in the protocol)) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Standard chemotherapy with Gemcitabine, Oxaliplatin and rituximab in case of B-cell lymphoma |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 8 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 76 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Israel |
Austria |
Belgium |
Czechia |
France |
Germany |
Netherlands |
Poland |
Portugal |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 7 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 7 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |